Gert de Wilde

Gert De Wilde serves as the Head of Translational Biology at Agomab Therapeutics since February 2023. With extensive experience at Galapagos since September 2013 as Director of Disease Biology, Gert De Wilde manages OMICs initiatives and leads a research team focused on integrating OMICS data for novel target identification. Previous roles include Head of Discovery at Arcarios NV/BV, Project Manager at TIGENIX NV, and Head of Biology at Devgen, where key responsibilities involved team management, project leadership in drug discovery, and preparation of investor presentations. Gert De Wilde holds a Ph.D. in Molecular and Cellular Biology from Ghent University.